Imlunestrant: Clinical Trials

12 trials of Imlunestrant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 active not recruiting, 2 recruiting, 1 not yet recruiting. 12 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 112Completed 6, Active not recruiting 3, Recruiting 2, Not yet recruiting 1
Phase 21Recruiting 1

Follow Imlunestrant: new trials by email Literature Review of Imlunestrant trials Research Report on Imlunestrant

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
PRT13722, Fulvestrant, Abemaciclib - Breast Cancer, Hormone-receptor-positive Breast Cancer
Phase 1RecruitingPrelude Therapeutics Incorporated2422026-11-162026-11-12
A Study of Imlunestrant (LY3484356) in Healthy Female Participants
Imlunestrant (Test), Imlunestrant (Reference), Omeprazole - Healthy
Phase 1Not yet recruitingEli Lilly and Company3432026-11-012026-11-05
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult
Phase 1 / Phase 2RecruitingEli Lilly and Company8802023-04-172026-07-07
A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer
LY3484356 - Breast Neoplasms
Phase 1Active not recruitingEli Lilly and Company172022-10-092026-04-13
A Study of Imlunestrant (LY3484356) in Healthy Women
Midazolam, Imlunestrant - Healthy
Phase 1CompletedEli Lilly and Company202022-09-122025-11-12
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
Imlunestrant, Repaglinide, Omeprazole - Healthy
Phase 1CompletedEli Lilly and Company1132022-07-072025-12-12
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
Imlunestrant - Hepatic Insufficiency, Healthy
Phase 1CompletedEli Lilly and Company272022-07-052025-11-12
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
LOXO-783, Fulvestrant, Imlunestrant - Breast Cancer
Phase 1Active not recruitingEli Lilly and Company2602022-05-112026-10-14
A Study of [¹⁴C]-LY3484356 in Healthy Female Participants
[¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV) - Healthy
Phase 1CompletedEli Lilly and Company162021-08-132025-12-05
A Study of LY3484356 in Healthy Female Participants
LY3484356, Omeprazole, Itraconazole - Healthy
Phase 1CompletedEli Lilly and Company822021-04-262025-12-11
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
LY3484356 - Breast Cancer
Phase 1CompletedEli Lilly and Company872021-04-212025-11-12
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
LY3484356, Abemaciclib, Everolimus - Breast Cancer, Advanced Breast Cancer
Phase 1Active not recruitingEli Lilly and Company3792019-12-102026-06-22

Conditions studied

Breast Neoplasms (6)  ·  Endometrial Neoplasms (2)  ·  Breast Diseases (1)  ·  Head and Neck Neoplasms (1)  ·  Hepatic Insufficiency (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Ovarian Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

Eli Lilly and Company (11)  ·  Prelude Therapeutics Incorporated (1)

Countries

United States (11)  ·  Belgium (4)  ·  France (4)  ·  Spain (4)  ·  Germany (3)  ·  Japan (3)  ·  Australia (2)  ·  China (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  Ireland (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Singapore (1)

Results publications

PMID 39241211, PMID 41423595

NIH funding

2019 (1), 2023 (1)